Docoh
Loading...

ALNY Alnylam Pharmaceuticals

News

From Benzinga Pro
A Bearish Sign Appears On Alnylam Pharmaceuticals's Chart
21 Jan 22
Markets, Movers, Trading Ideas
If history is any guide, there may be trouble ahead for shares of Alnylam Pharmaceuticals (NASDAQ:ALNY). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock.
Alnylam' Reveals Detailed 18-Month Data From Vutrisiran Trial In Inherited Disease
21 Jan 22
Biotech, News, Health Care, General
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) has announced
The Daily Biotech Pulse: Kura Lifts Clinical Hold On Blood Cancer Trial, Intuitive Surgical Earnings, Sorrento's Omicron Antibody Treatment Effective
21 Jan 22
Biotech, Earnings, News, Penny Stocks, Small Cap, FDA, General
Here's a roundup of top developments in the biotech space over the last 24 hours.
Alnylam Highlights 18-Month Results From HELIOS-A Phase 3 Study Of Vutrisiran: All Secondary Endpoints Were Met; BZ NOTE: Co. Previously Announced All Primary, Secondary Endpoints Met On 9-Month Basis; However, Release Today Does Not Mention Primary
21 Jan 22
Biotech, News, FDA, General
– Vutrisiran Met All 18 Month Secondary Endpoints, Including Statistically Significant Improvements in Neuropathy Impairment, Quality of Life (QoL), Gait Speed, Nutritional Status and Overall Disability, Relative
What 10 Analyst Ratings Have To Say About Alnylam Pharmaceuticals
20 Jan 22
Analyst Ratings
Over the past 3 months, 10 analysts have published their opinion on Alnylam Pharmaceuticals (NASDAQ:ALNY) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
HC Wainwright & Co. Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $350
20 Jan 22
News, Price Target, Analyst Ratings
HC Wainwright & Co. analyst Patrick Trucchio maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and raises the price target from $250 to $350.
n-Lorem Foundation Reports Partnership With Alnylam To Expand Technology Access To RNAi Therapeutics For Patients With Nano-Rare Diseases, No Terms Disclosed
18 Jan 22
Biotech, News, FDA, General
Alnylam’s RNAi expertise and financial donation bolster efforts to reach more nano-rare patients where a RNAi targeted approach would be most appropriate SAN DIEGO--(BUSINESS WIRE)-- n-Lorem, a nonprofit
Morgan Stanley Maintains Overweight on Alnylam Pharmaceuticals, Lowers Price Target to $215
18 Jan 22
News, Price Target, Analyst Ratings
Morgan Stanley maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Overweight and lowers the price target from $226 to $215.
The Week Ahead In Biotech (Jan 16-22): Focus On Data Presentations And IPOs In Holiday-Shortened Week
16 Jan 22
Biotech, Earnings, News, Penny Stocks, Small Cap, IPOs, Top Stories, General
Biotech stocks posted losses for the third straight week, as the sector reacted to broader market weakness and announcements out of the 2022 JPMorgan Healthcare conference.
Novartis Announced Three-Year Collaboration With Alnylam to Explore Targeted Therapy to Restore Liver Function
6 Jan 22
News
Novartis today announced a collaboration with Alnylam to leverage Alnylam's proven, proprietary siRNA technology to inhibit a target discovered at the Novartis Institutes for BioMedical Research, potentially leading to development of a treatment designed to promote the regrowth of functional liver cells and to provide an alternative to transplantation for patients with liver failure.
Benzinga's Top Ratings Upgrades, Downgrades For January 3, 2022
3 Jan 22
Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings
Upgrades
What 9 Analyst Ratings Have To Say About Alnylam Pharmaceuticals
3 Jan 22
Analyst Ratings
Analysts have provided the following ratings for Alnylam Pharmaceuticals (NASDAQ:ALNY) within the last quarter:
Piper Sandler Upgrades Alnylam Pharmaceuticals to Overweight, Raises Price Target to $208
3 Jan 22
News, Upgrades, Price Target, Analyst Ratings
Piper Sandler analyst Edward Tenthoff upgrades Alnylam Pharmaceuticals (NASDAQ:ALNY) from Neutral to Overweight and raises the price target from $181 to $208.
Attention Biotech Investors: Mark Your Calendar For January PDUFA Dates
31 Dec 21
Biotech, News, Penny Stocks, Previews, Small Cap, FDA, Top Stories, Trading Ideas, General
Regulatory decisions by the U.S. Food and Drug Administration in December turned out to be mostly positive. Among the treatment options that were greenlighted in the month were two new molecular entities.
51 Biggest Movers From Yesterday
28 Dec 21
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers Microbot Medical Inc. (NASDAQ: MBOT) shares climbed 65.1% to close at $8.95 on Monday after the company announced a strategic collaboration with Stryker Corporation to develop the LIBERTY robotic system for neurovascular applications.
12 Health Care Stocks Moving In Monday's Intraday Session
27 Dec 21
Intraday Update, Markets, Movers
34 Stocks Moving In Monday's Mid-Day Session
27 Dec 21
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Gainers Microbot Medical Inc. (NASDAQ: MBOT) shares jumped 69.6% to $9.19 after the company announced a strategic collaboration with Stryker Corporation to develop the LIBERTY robotic system for neurovascular applications.
FDA Approves Alnylam - Novartis' Leqvio As the First siRNA To Reduce Bad Cholesterol
23 Dec 21
Biotech, News, Health Care, FDA, General
The
The Daily Biotech Pulse: Novartis Snags Twin FDA Nods, Novavax Positive Vaccine News Continues, Arcutis Psoriasis Application Accepted For Review
23 Dec 21
Biotech, News, Penny Stocks, Small Cap, FDA, General
Here's a roundup of top developments in the biotech space over the last 24 hours.
Alnylam Pharma Reports Comments On FDA Approval Of Leqvio Approved To Reduce Low-Density Lipoprotein Cholesterol
22 Dec 21
Biotech, News, FDA, General
– Leqvio® Becomes Fourth RNAi Therapeutic Approved by U.S. FDA and First and Only for Lowering LDL-C in Atherosclerotic Cardiovascular Disease (ASCVD) Which Can Affect Up to 30 Million Americans

Press releases

From Benzinga Pro
Alnylam Presents Positive 18-Month Results from HELIOS-A Phase 3 Study of Investigational Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy
21 Jan 22
Press Releases
– Vutrisiran Met All 18 Month Secondary Endpoints, Including Statistically Significant Improvements in Neuropathy Impairment, Quality of Life (QoL), Gait Speed, Nutritional Status and Overall Disability, Relative to
Ceptur Therapeutics Launches with $75M Series A Financing to Advance RNA Therapeutics Based on Proprietary U1 Adaptor Technology
19 Jan 22
Press Releases
Financing co-led by venBio Partners & Qiming Venture Partners USA with participation from strong syndicate of new and existing investors Pioneering new wave of oligonucleotide-based genetic medicines through
n-Lorem Foundation Partners with Alnylam to Expand Technology Access to RNAi Therapeutics for Patients with Nano-rare Diseases
18 Jan 22
Press Releases
Alnylam's RNAi expertise and financial donation bolster efforts to reach more nano-rare patients where a RNAi targeted approach would be most appropriate n-Lorem, a nonprofit Foundation, discovering and providing
Alnylam to Present Full 18-Month Results from the HELIOS-A Phase 3 Study of Vutrisiran at the Société Francophone du Nerf Périphérique Annual Meeting
14 Jan 22
Press Releases
– Company to Host Conference Call January 21st at 8:30 am ET to Discuss Results – Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that the Company will present full
Soleo Health to Administer OXLUMO™ for the Treatment of Primary Hyperoxaluria Type 1
11 Jan 22
Press Releases
Company to Administer First FDA-Approved PH1 Drug to Lower Urinary Oxalate Levels Soleo Health, an innovative leader and national provider of complex specialty pharmacy services, announced today it has access to
Alnylam Announces Preliminary* Fourth Quarter and Full Year 2021 Global Net Product Revenues and Provides Additional Updates
9 Jan 22
Press Releases
– Achieved Full Year 2021 Preliminary Global Net Product Revenues of $662 Million, Representing 83% Annual Growth Compared to 2020 – – Maintained Strong Balance Sheet with Year-End Cash and Investments Balance of
Alnylam Announces Collaboration with Novartis to Explore Targeted Therapy to Restore Liver Function
6 Jan 22
Press Releases
– Agreement will Bring Alnylam's Proprietary siRNA Technology to Bear on Liver Target Identified by Novartis Researchers – – Alnylam and Novartis have Agreed to Collaborate on Discovery and Development of siRNA-based
Alnylam Announces Promotion of Dr. Akshay Vaishnaw to President
4 Jan 22
Press Releases
– Consistent Scientific Leadership Focused on Sustainable Innovation – Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today announced that Akshay Vaishnaw, M.D., Ph.D. has been
Alnylam to Webcast Presentation at 40th Annual J.P. Morgan Healthcare Conference
3 Jan 22
Press Releases
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 40th Annual J.P. Morgan Healthcare Conference, being held
Alnylam Comments on FDA Approval of Leqvio®, the First siRNA (RNAi Therapeutic) Approved to Reduce LDL-C
22 Dec 21
Press Releases
– Leqvio® Becomes Fourth RNAi Therapeutic Approved by U.S. FDA and First and Only for Lowering LDL-C in Atherosclerotic Cardiovascular Disease (ASCVD) Which Can Affect Up to 30 Million Americans – Alnylam
Alnylam Submits CTA Application for ALN-APP, an Investigational RNAi Therapeutic for the Treatment of Alzheimer's Disease and Cerebral Amyloid Angiopathy
22 Dec 21
Press Releases
- Company Expects to Initiate a Phase 1 Study in Early-Onset Alzheimer's Disease in Early 2022, with Initial Human Data at or Around Year-End 2022 - - ALN-APP Marks the Industry's First-Ever RNAi Therapeutic Program
Alnylam Publishes 3rd Annual Patient Access Philosophy Report Demonstrating Steady Access to Approved Therapies as Company Enters New Geographies
21 Dec 21
Press Releases
– Annual progress report highlights the breadth of innovative and collaborative initiatives that support accessibility of RNAi therapeutics for people who can benefit worldwide – Alnylam Pharmaceuticals, Inc.
Alnylam Initiates Phase 2 Study of Lumasiran in Patients with Recurrent Kidney Stone Disease
20 Dec 21
Press Releases
– Phase 2 Study will Evaluate the Safety and Efficacy of Lumasiran in Patients with Recurrent Kidney Stone Disease and Elevated Urinary Oxalate Levels – Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi
Alnylam Submits Regulatory Applications to the U.S. Food and Drug Administration and European Medicines Agency to Support Label Expansion for OXLUMO® for the Treatment of Advanced Primary Hyperoxaluria Type 1
14 Dec 21
Press Releases
-Findings From the ILLUMINATE-C Phase 3 Study Showed Substantial Reductions in Plasma Oxalate in PH1 Patients with End-Stage Kidney Disease, Including Patients on Hemodialysis- Alnylam Pharmaceuticals, Inc.
Direxion Launches mRNA ETF (MSGR)
9 Dec 21
Press Releases
NEW YORK, Dec. 9, 2021 /PRNewswire/ -- Direxion announced today the launch of the Direxion mRNA ETF (Ticker: MSGR). MSGR invests in companies believed to be at the forefront of the development and application of
Alnylam Ranks #1 in Boston Globe's Top Places to Work List for 2021
2 Dec 21
Press Releases
- Recognition Marks Alnylam's Seventh Year in a Row on this Prestigious List, and its First Time Ranking #1 - Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today announced it has
Alnylam Announces 2022 Product and Pipeline Goals and Provides Program Updates at R&D Day
19 Nov 21
Press Releases
− Introduces New Near-Term Opportunity for Vutrisiran in Stargardt Disease, Expected to Enter Phase 3 Development in Late 2022 – – Adds New Preclinical Cardiovascular Disease Programs, GEMINI-CVR and "Gene X," with
Alnylam Presents New Data for Zilebesiran, an Investigational RNAi Therapeutic for the Treatment of Hypertension, at the American Heart Association Scientific Sessions 2021
13 Nov 21
Press Releases
– Single Doses of Investigational Zilebesiran Resulted in Sustained Serum Angiotensinogen and Blood Pressure Reductions Through Six Months, Supporting Quarterly and Potentially Biannual Dosing – – Blood Pressure
Alnylam Initiates KARDIA-2 Phase 2 Study of Investigational Zilebesiran (ALN-AGT) in Patients with Inadequately Controlled Hypertension
8 Nov 21
Press Releases
– KARDIA-2 will Evaluate Efficacy and Safety of Zilebesiran when Used in Combination with Conventional Antihypertensive Medications – Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company,
Alnylam Presents Positive Results from ILLUMINATE-C Phase 3 Study of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1
5 Nov 21
Press Releases
- Lumasiran Resulted in Substantial Reductions in Plasma Oxalate in PH1 Patients with Severe Renal Impairment - Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today